The Navigator Co SA (STU:PO9) reports a 20% EBITDA increase and strategic investments in sustainability, despite operational disruptions and geopolitical pressures.

The Navigator Co SA (POELF) showcases financial stability and strategic growth initiatives despite operational disruptions and market pressures.

If you’re wondering what to do with Mota-Engil SGPS stock, you’re definitely not alone. With shares up an outstanding 131.0% over the past year and an incredible 425.1% gain over the last three years, investors are right to question if the growth story still has room to run. Just in the past week, the stock surged another 13.0%. Part of this can be traced back to a wave of positive market sentiment in the infrastructure and construction sectors, fueled by hefty contract wins across Southern...

Navigator Company (ENXTLS:NVG) has been drawing attention lately, and investors might be wondering what has sparked this renewed focus. While there hasn't been a headline-making event or dramatic shift in the business, the current move in Navigator’s stock serves as a reminder to take a closer look at the fundamentals. Sometimes, a period of subtle price changes can be just as meaningful as splashy news and can prompt savvy investors to ask if there is an opportunity the market is...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.